PRINCETON, N.J., Jan. 5, 2011 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced that Catherine Derasp, RN, has joined the Company as Vice President, Clinical Operations of the Company’s Phase I clinics.
“We are thrilled to have Catherine join us,” said Riaz Bandali, President, Early Stage Development. “Catherine’s commitment to continual improvement and expertise in multi-site Phase I clinical operations, quality systems, and training brings the right combination of knowledge and experience to the PharmaNet Phase I clinical organization.”
Ms. Derasp will oversee the management of the Company’s 350 bed Phase I clinical operations that are located in Montreal and Quebec City, Canada. In addition to first-in-man and proof-of-concept phase I clinical services, Ms. Derasp will be responsible for a variety of studies in special populations, cardiac safety testing, and drug-drug interaction studies.
Ms. Derasp has more than 15 years of experience working for Phase I clinical research organizations. Her various leadership roles included managing global multi-site operations with specialization in operational quality and process improvement.
About PharmaNet Development Group, Inc.
PharmaNet Development Group, a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit www.PharmaNet.com.
Contact: | |
Anne-Marie Hess | |
Phone: (609) 951-6842 | |
E-mail: ahess@pharmanet.com | |
SOURCE PharmaNet Development Group, Inc.
